Axon workstation wins R&D award
Thursday, 31 July, 2003
ASX-listed Axon Instruments has picked up an R&D 100 award for its OpusExpress 6000A electrophysiology workstation.
The awards, which recognise the 100 most innovative new technologies of the previous 12 months, is made by the editors of R&D Magazine and a panel of independent judges.
Axon's OpusExpress system is described by the company as the first commercially available multi-channel, automated oocyte voltage-clamp recording system, which makes possible high-throughput electrophysiology and improves the efficiency of the drug discovery process.
In a statement, Axon CEO Alan Finkel said high-throughput electrophysiology was the wave of the future.
"It is changing the way that pharmaceutical companies search for ion-channel drugs," Finkel said.
Ion channels have been implicated in a number of diseases, including cystic fybrosis, epilepsy, muscular dystrophy, migraine and cancer. The Human Genome project identified between 300 and 400 ion-channel genes in humans.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
